CASI Pharmaceuticals (CASIF) Construction in Progress (2021 - 2023)
CASI Pharmaceuticals' (CASIF) quarterly Construction in Progress came in at $23000.0 in Q4 2023, down 99.6% YoY from $5.7 million in Q4 2022, and down 99.6% on a QoQ basis from $5.7 million in Q4 2022.
CASI Pharmaceuticals (CASIF) Construction in Progress (2021 - 2023) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 3 years of Construction in Progress data on file, last reported at $23000.0 in Q4 2023.
- Quarterly Construction in Progress fell 99.6% year-over-year to $23000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $23000.0 (down 99.6% YoY) and the FY2023 annual result came in at $23000.0, down 99.6% from the prior year.
- Construction in Progress eased to $23000.0 in Q4 2023, from $5.7 million in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $12.1 million in Q4 2021 to a low of $23000.0 in Q4 2023.
- A 3-year average of $5.9 million and a median of $5.7 million in 2022 frame the typical range for Construction in Progress.
- Annual changes were most pronounced in 2022 — Construction in Progress plunged 52.64% — and 2023, when it slumped 99.6%.
- Tracing CASIF's Construction in Progress over 3 years: stood at $12.1 million in 2021, then sank by 52.64% to $5.7 million in 2022, then tumbled by 99.6% to $23000.0 in 2023.
- The last three Construction in Progress figures came in at $23000.0 (Q4 2023), $5.7 million (Q4 2022), and $12.1 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 152.67 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 23,000.00 |
| Dec 31, 2022 | 5.73 Mn |
| Dec 31, 2021 | 12.10 Mn |